Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6244879 | 0.89 | SLC6A4 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6345745 | 0.88 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6344011 | 0.84 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6240201 | 0.84 | ADAM17 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6240952 | 0.81 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6347109 | 0.81 | ADAM17 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6239804 | 0.81 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6242531 | 0.80 | GRIA4 (0.48) | HCRTR2NPY5RGRIA4 | |
| SCHEMBL6353147 | 0.79 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6345870 | 0.79 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395550-B1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | CANTELL BUDDY EUGENE (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1395550-A1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002098847-A1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | GRIN2B, GRIN2A, GRIN1 | PSEN1 305/4885PSEN2 258/4885APH1B 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.